Connect with us

Futures, Global Stocks Hover At All Time High As Q1 Earnings Begin

Futures, Global Stocks Hover At All Time High As Q1 Earnings Begin

Global stock markets and US equity index futures dipped modestly with shares in Europe and Asia as traders weighed inflation risks, an uneven global recovery and the latest…

Published

on

Futures, Global Stocks Hover At All Time High As Q1 Earnings Begin

Global stock markets and US equity index futures dipped modestly with shares in Europe and Asia as traders weighed inflation risks, an uneven global recovery and the latest upbeat economic outlook from Washington. After sprinting to close at an all time high on optimism that vaccination programs and the easing of lockdowns to combat COVID-19 would bode well for an economic rebound, S&P 500 futures were cautious to start the new week as investors waited to see whether U.S. earnings would justify sky-high valuations, while a rally in bonds could be tested by what should be strong readings for U.S. inflation and another round of blockbuster retail sales this week.

MSCI’s All Country World Index was down 0.25% after the start of European trading, off Friday’s record high. The gauge’s price-to-earnings ratio is at its highest level since early 2010. At 07:30 a.m. ET, Dow E-minis were down 43 points, or 0.13%, S&P 500 E-minis were down 5 points, or 0.13% and Nasdaq 100 E-minis were down 38 points, or 0.27%.

Some notable premarket movers:

  • Tesla rose about 2% in premarket trading after Canaccord Genuity upgraded the electric-car maker’s shares to “buy” and said the company could become “the brand” in energy storage.
  • Uber’s delivery business set an all-time record, crossing a $52BN annualized Gross Bookings run-rate in March, growing more than 150% year-over-year.
  • Alibaba jumped 6.3% after the ecommerce company said it does not expect any material impact from the antitrust crackdown in China which cost it $2.8 billion, one which will push it to overhaul how it deals with merchants. Over a third of the stock is held by U.S. investors, and it makes up more than 8% of the MSCI EM index.
  • Shares of Nuance Communications Inc surged about 23% as a source said Microsoft Corp is in advanced talks to buy the artificial intelligence and speech technology company at about $16 billion.

In Sunday's 60 Minutes episode, Fed Chair Jerome Powell on Sunday said the U.S. economy is at an “inflection point” with expectations that growth will pick up speed in the months ahead, but also risks if a hasty reopening leads to a continued increase in coronavirus cases.

This week Q1 earnings season begins with the big banks reporting, and S&P 500 earnings are expected to have jumped a massive 25% in the quarter from a year ago, the biggest quarterly gain since 2018, when tax cuts under former President Donald Trump drove a surge in profit growth. Results from big U.S. banks Goldman Sachs, JPMorgan and Wells Fargo will pour in on Wednesday, kicking off the first-quarter earnings season where investors will look for reasons to support a stock market at all-time highs.

And while some like JPM said the rally had still room to run, others like Morgan Stanley noted that despite the S&P 500 making new all-time highs, small cap stocks represented by the Russell 2000 small cap index have underperformed the S&P 500 by 8% since peaking on March 12.

“In my view, the breakdown of small caps and cyclicals is a potential early warning sign that the actual reopening of the economy will be more difficult than dreaming about it,” said Michael Wilson, the bank’s chief U.S. equity strategist and chief investment officer. “Small caps and cyclicals have been stellar outperformers over the past year. In essence, they were discounting the recovery and reopening that we are about to experience. However, now we must actually do it and with that comes execution risk and potential surprises that aren’t priced.”

The VIX index ticked slightly higher to 17.48, having hit its lowest level since March 2020 on Friday. “Renewed bouts of elevated volatility are likely over the coming months, in our view,” said Mark Haefele, chief investment officer at UBS Global Wealth Management. “Investors can take advantage of this backdrop, however. Low volatility at present reduces the cost of locking in downside protection.”

U.S. growth and tech stocks saw something of a revival last week as U.S. 10-year Treasury yields retreated to 1.65%, from a 14-month top of 1.776%. “Low inflation and dovish central banks should limit the rise in bond yields during the recovery,” said Andrew Pease, global head of investment strategy at Russell Investments.

In Europe, retailers and travel companies led declines on the Stoxx Europe 600 Index. European shares eased off record highs as investors held off from making big bets before earnings season. The pan-European STOXX 600 index was down 0.2% with the Stoxx Europe 600 Basic Resources Index dropping as much as 1.4% after surging inflation in China and the U.S. triggered possible measures to cool prices and boosted the dollar. Britain’s domestically focused FTSE mid 250 index held 0.2% below a record high as shops, pubs, gyms and hairdressers re-opened after three months of lockdown. The UK’s more export-oriented FTSE 100 fell 0.3%, Germany’s DAX and France’s CAC 40 both traded flat. Italy’s FTSE MIB gained nearly half a percent. Here are some of the biggest European movers today:

  • Suez shares rise as much as 8.5% after the company agreed to sell itself to Veolia, which jumped as much as 9.4%. Barclays said the deal was a significant positive for both companies.
  • DiaSorin shares jump as much as 11%, the biggest gain in the Stoxx 600, after the Italian company agreed to acquire Luminex Corp. for about $1.8b. Earlier, Berenberg said the agreement, while “no huge surprise,” is a “good deal.”
  • Teleperformance shares gain as much as 4.2%, extending a record high, after reporting 1Q growth that analysts said was stronger than expected. The beat was in part due to support services associated with governmental Covid vaccination programs, Citi wrote in a note.
  • HeidelbergCement shares jump as much as 1.7% after Barclays said it expected to see positive comments on pricing from cement companies in 1Q updates. The broker said HeidelbergCement was likely to see robust growth against easy comparables.
  • HelloFresh shares fall as much as 5.1% as the stock took a step back after rising to a seven-week high on Friday. Citi said trends for both HelloFresh’s U.S. and international businesses softened into the month-end of March.

Earlier in the session, Asian stocks fell for a second day, with India and China leading a broad decline in regional equities. India’s key stock gauges slumped more than 3% as the nation battled with a record surge in coronavirus cases. China's CSI 300 Index fell more than 1.5%, with materials stocks tumbling after the Chinese government vowed to tighten controls on commodities. While Alibaba rallied in Hong Kong as a record penalty on the group was seen lifting a regulatory overhang on its stock, shares of peers including Tencent and Meituan slid, weighing on the Hang Seng. Japanese stocks dropped as the slow pace of domestic vaccinations weighed on investor sentiment, while Australian stocks declined as the nation abandoned its vaccine timeline amid delays. Technology and consumer discretionary sectors were the biggest drags on the MSCI Asia Pacific Index. The gauge ended flat last week, with intraday swings dropping to the lowest since the start of the year, as traders awaited more clarity on the region’s economic recovery and vaccine rollout.

Looking at just China, local stocks fell by the most in three weeks amid weak turnover on Monday, as the material sector tumbled after the government vowed to tighten controls on commodities. The CSI 300 Index dropped 1.7%, closing below the 5,000 key support level for the first time since March 25.

Hong Kong’s Hang Seng Index declined 0.9% as of 3:40 p.m. local time, as Alibaba’s gain failed to offset losses of its tech peers, which are expected to face scrutiny by Beijing following a record penalty for the e-commerce giant. Material stocks led the retreat in A shares as the government plans to step up controls on the raw material market to help limit costs for companies pressured by surging commodities prices. Wanhua Chemical, Zijin Mining and Ganfeng Lithium are among the top 10 drags on the CSI 300 gauge. Investors are awaiting clues on where China’s monetary policy is heading after soaring commodity costs sent China’s producer prices to jump by the most in more than two years last month. The government is scheduled to report its money supply and March new yuan loans by Thursday, which are important proxies for liquidity conditions in the country. “If inflation picks up too quickly, it’s possible that the central bank will do something to counter that, which could be bad for the market,” said Zhang Gang, a Central China Securities Co. strategist, by phone. Turnover of the CSI 300 Index was 8.4% lower than its 30-day average while trading volume in Hong Kong was 34% less than its average, according to Bloomberg-compiled data

In Japan, stocks also dropped as the slow pace of domestic vaccinations weighed on investor sentiment despite gains on Wall Street last week. Electronics and chemicals makers were the heaviest drags on the Topix, which fell for the past three weeks. Shin-Etsu Chemical and Fast Retailing weighed on the Nikkei 225 Stock Average. Yaskawa Electric slid the most in 13 months on weaker-than-expected earnings and analyst downgrades. “The delay in vaccinations is a drag on Japan’s business sentiment as well as the service sector,” said Norihiro Fujito, the chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities in Tokyo. “Because of this, local equities aren’t quite able to mirror moves in U.S. equities.”

Australia's S&P/ASX 200 index fell 0.3% to close at 6,974.00 after Australia abandoned its vaccine timeline amid delays. Prime Minister Scott Morrison said he won’t set a new target date for all Australians to receive their first Covid-19 vaccine dose, as health concerns about the AstraZeneca Plc shot and European export restrictions delay the rollout.

In FX, the Bloomberg Dollar Spot Index dipped after paring earlier gains; The euro hovered around $1.19 while European government bonds advanced, led by Italy. The pound led gains among Group-of-10 peers following its worst week versus both the dollar and euro this year as non-essential retailers as well as pubs and restaurants with outdoor space reopen across England after almost 100 days of lockdown; a survey showed U.K. business leaders were the most optimistic on record last quarter. The yen advanced as a decline in regional shares underpinned demand for haven assets.

In rates, Treasuries were little changed into early U.S. session with long-end outperforming. Treasury 10-year yield around 1.664% outperforms gilts by ~1bp while cheapening by ~1.5bp vs bunds, which were supported after ECB President Lagarde said it’s ready to extend and expand PEPP if necessary.  Treasuries traded heavy during Asia session with supply pressure weighing, while Aussie bonds underperformed ahead of 2032 syndicated bond issue set to price Tuesday. The U.S. auction cycle starts with $58b 3-year note sale at 11:30am ET, followed by $38b 10-year reopening at 1pm ET; it concludes with $24b 30-year reopening Tuesday.

A pullback in the benchmark 10-year bond yield from 14-month highs in April eased worries about higher borrowing costs, helping richly valued high-growth technology stocks gain ground and drive the S&P 500 and the Dow to record levels. U.S. consumer price data for March and $271 billion of U.S. Treasury auction this week could end a recent lull in the bond market, reigniting a rise in yields that worried investors in the first quarter.

In commodities, gold prices were idling at $1,737 an ounce, having failed to sustain a top of $1,758 last week.Oil prices edged higher in rangebound trade on Monday on optimism over a rebound in the U.S. economy as coronavirus vaccinations accelerate, though rising COVID-19 cases in other parts of the world kept a lid on prices. Brent rose 1% to $63.61 a barrel. U.S. crude rose 0.9% to $59.86.

Bitcoin briefly rose above $61,000 before fading gains.

Data out this week is expected to show U.S. inflation jumped in March. Retail sales are seen surging, perhaps even with a double-digit gain. The U.S. Treasury is also set to test demand with offers of $100 billion in debt this week: U.S. supply is front-loaded, kicking off with 3- and 10-year note sales Monday. There is a packed calendar of appearances by Fed officials.

Market Snapshot

  • S&P 500 futures down 0.2% to 4,111.00
  • STOXX Europe 600 down 0.3% to 435.95
  • MXAP down 0.8% to 204.84
  • MXAPJ down 1.1% to 680.25
  • Nikkei down 0.8% to 29,538.73
  • Topix down 0.2% to 1,954.59
  • Hang Seng Index down 0.9% to 28,453.28
  • Shanghai Composite down 1.1% to 3,412.95
  • Sensex down 3.5% to 47,854.80
  • Australia S&P/ASX 200 down 0.3% to 6,973.96
  • Kospi up 0.1% to 3,135.59
  • Brent Futures up 0.5% to $63.25/bbl
  • Gold spot down 0.3% to $1,738.84
  • U.S. Dollar Index up 0.02% to 92.182
  • German 10Y yield fell 1.6 bps to -0.319%
  • Euro down 0.02% to $1.1897

Top Overnight News from Bloomberg

  • Federal Reserve Chair Jerome Powell said the U.S. economy is at an “inflection point” with stronger growth and hiring ahead thanks to rising vaccinations and powerful policy support, but Covid-19 remains a threat
  • Angela Merkel’s conservative bloc is poised to pick the winner in a two-man showdown over its candidate to succeed her as German chancellor. The Christian Democratic Union and its smaller Bavarian sister-party, the Christian Social Union, are holding separate leadership meetings Monday.
  • A lasting surge in prices would likely convince policy makers that it’s time to tap the brakes on expansionary measures adopted in the pandemic, like high public spending or low borrowing costs. That’s why Tuesday’s consumer-price data in the U.S. will be so closely watched -- though it’ll take more than a single month’s numbers to change minds

A quick look at global markets courtesy of Newsquawk

Asian equity markets began the week subdued and US equity futures marginally pulled back from record levels with participants tentative ahead of the start of US earnings season and this week’s key data releases including Chinese trade tomorrow, as well as GDP, Industrial Production and Retail Sales data on Friday. ASX 200 (-0.3%) was pressured with gold miners and real estate the underperformers of the broad subdued picture across Australia's sectors amid vaccine-related pessimism after the government abandoned its vaccination target of inoculating the entire population by year-end with PM Morrison refraining from setting a new target. Nikkei 225 (-0.8%) swung between gains and losses with price action at the whim of a firmer currency and after restrictions were reimposed for Tokyo, Kyoto and Okinawa. KOSPI (+0.1%) was relatively flat with downside cushioned following a continued surge in exports during the first 10 days in April and with SK Innovation and LG Chem lifted after they agreed to settle a trade secret dispute whereby SK Innovation will pay USD 1.8bln to LG Chem’s unit which boosted SK Innovation shares by double digits as it paves the way for the Co. to complete building an EV lithium-ion battery plant in Georgia that will supply batteries to Ford and Volkswagen. Hang Seng (-0.9%) and Shanghai Comp. (-1.1%) weakened ahead of key Chinese data releases and amid lingering tensions in the region as US Secretary of State Blinken noted the US is concerned about China's aggressive actions against Taiwan and warned it could be a "serious mistake" for anyone to try to change the status quo by force. Focus was also on Alibaba shares after Chinese regulators imposed a USD 2.8bln fine for the Co. for abusing market dominance which weighed on other tech giants including Tencent and Meituan Dianping on concerns they could be next to face tighter scrutiny, although Alibaba shares actually rallied despite the record penalty as it was said to just account for 4% of the Co.’s domestic revenue in 2019 and with the Co. not expecting any material impact on its business from the change of exclusivity arrangements imposed by regulators. Indian markets suffered with the Nifty (-3.3%) heavily pressured from COVID-19 concerns amid another record daily increase in infections which pushed India back above Brazil to the 2nd spot of countries worst impacted by the pandemic. Finally, 10yr JGBs were flat despite the lacklustre picture across stocks, with price action dejected after Friday’s retreat and amid the absence of the BoJ purchases in the market today, while operations from the RBA and RBNZ who were in the market for AUD 2bln and NZD 170mln of government bonds had little effect on their respective yields.

Top Asian News

  • Six New Unicorns in Four Days Marks Historic Boom for India Tech
  • Low Efficacy of China’s Vaccines Sparks a Stir on Social Media
  • Korean ‘Webtoons‘ Firm Eyes $18 Billion Value from IPO
  • Japan’s Slow Vaccine Rollout Pushes Back Recovery Time Frame

European equities (Euro Stoxx 50 Unch) have kicked the week off with little in the way of firm direction. Macro drivers remain very much the same in Europe as pessimism from current lockdowns is expected to subside at some stage to a more upbeat outlook as the European vaccination effort picks up steam. In the US, strong data continues to accompany a successful vaccine rollout, which could see the nation reach herd immunity by around May. All of which comes amidst a highly support monetary and fiscal backdrop, whilst market participants also hope that some of the more aggressive elements of the Democratic Party tax plans can be curbed. This week sees US earnings season kick-off in earnest with some of the large-cap banks due to report. Goldman Sachs highlights that consensus currently forecasts aggregate sales growth of 5% and EPS growth of 19%. From a sectoral standpoint, GS notes that “consumer Discretionary is anticipated to pace the market with 97% year/year EPS growth powered by an 11% rise in sales”. Back to Europe, sectors are currently broadly lower across the board with the exception of Autos & Parts, which have been supported by the likes of Continental (+1.7%), Daimler (+1.8%) and BMW (+1.3%). To the downside, some of the other more cyclically-exposed stocks lag, with losses seen in Basic Resources, Retail, Oil & Gas and Banks. In terms of stock specifics, Diasorin (+7.9%) sit at the top of the Stoxx 600 after agreeing to purchase Luminex (+10% pre-market) for USD 37/shr in a USD 1.8bln deal. Suez (+8%) and Veoilia (+9) shares have been supported by news that they have come to an agreement, allowing for the merger of the two companies. Finally, another deal to watch out for is the potential acquisition of Nuance Communications (+21% pre-market) by Microsoft (+0.3% pre-market) for circa USD 16bln, with sources suggesting that an announcement could be made this week.

Top European News

  • Ardian Raises $8.9 Billion for European Private Equity Buyouts
  • Euronav Drops Most in a Year as ING Downgrades on Spot Rates
  • Hammerson in Talks to Sell U.K. Retail Parks to Brookfield
  • Merkel Bloc Heads for Risky Decision on Chancellor Candidate

In FX, it was a somewhat choppy start to the week for the broader Dollar and Index, albeit in a relatively contained range with the upside conviction seen in early European trade abating - the intraday band currently stands at 92.331-091. The weekend saw remarks from Fed Chair Powell, who stuck to his guns with emphasis on the labour market, whilst noting the economy is recovering better than he had expected, but virus flare-ups remain a significant risk. On that note, it is worth keeping on the radar the White House semiconductor summit slated for today (time TBC), as around 20 heavy-cap companies convene to discuss the chip shortage and its knock-on effect on auto production and subsequently jobs. From a fiscal standpoint, reports suggest US President Biden aims to complete the infrastructure program by the summer and is open to cooperate on the structure of the spending plan – although the proposal drew for Republicans last week. Key risk events for the European session remain on the lighter side, although the state-side Note auctions (3s, 10s) may garner attention. Looking ahead, the week is abundant with risk events, including US inflation, Fed speaks, and the official start of US earnings season, which could induce some sentiment-driven Dollar flows.

  • GBP, EUR: Mixed fortunes for the core European currencies with Sterling outpacing the Single Currency amidst some technical influence alongside reports that the UK and EU are reportedly nearing an agreement regarding implementation of post-Brexit trading laws for Northern Ireland, whilst ECB speakers offered little in terms of the impetus for the EUR. The divergence also comes against the backdrop of the UK easing its COVID-related restrictions as the Eurozone observes more stringent rules. As such, EUR/GBP has been on a steady downward trajectory since the European open as the pair eyes its 50 DMA at 0.8635 vs 0.8695 at best. Cable as such has been bolstered from its 1.3667 base, back above its 100 DMA (1.3689) to a high just shy of 1.3750 ahead of the 8 April high (1.3782) and the 1.3800 psychological mark. EUR/USD meanwhile relinquished its 1.1900-status in early hours and dipped below its 200 DMA (1.1898) as it inched closer to 1.1850 and its 21 DMA (1.1846), before the waning Dollar took the pair back to 1.1900, whilst above-expected but outdated February retail sales data unsurprisingly failed to spur any action.
  • AUD, NZD, CAD: All now narrowly firmer against the Buck to varying degrees, with the Loonie the laggard amid early losses across the crude complex, with the Aussie and Kiwi initially succumbing to the modestly firmer Buck and softer risk tone alongside negative omens emanating from the downbeat Chinese performance. AUD/USD has picked up pace north of 0.7600, having had earlier dipped below the figure, whilst upside levels see the 100 and 21 DMA both converging at 0.7657. NZD/USD holds a 0.70+ status with the round the nearest point of support and the 21 DMA (0.7061) the closest point of resistance above 0.7050.
  • CHF, JPY: Elsewhere, the CHF and JPY are narrowly mixed with USD/JPY reacting to the soured risk tone as it dips below 109.50 (vs 109.76) to a current low around 109.30, whilst the Swissie remains flat in a tight range vs the USD and EUR whilst weekly sight deposits only portrayed incremental changes W/W.

In commodities, WTI and Brent front month futures have been subject to yet another choppy European morning as the complex attempts to tackle the COVID-related demand headwinds alongside supply-side risks emanating from several geopolitical standoffs. Kicking off with the latter, the most notable development has been reports that Yemeni Houthis have bombarded areas in Saudi Arabia with drones and ballistic missiles, with 10 drones reportedly targeting Aramco facilities and some military sites - markets are still awaiting confirmation from the Saudi side. Elsewhere, Iran experienced an accident at its Natanz nuclear operation with Tehran pointing the finger at its adversary Israel - although uranium enrichment has not been impacted and more sophisticated centrifuges will soon be introduced. On this note, Iranian nuclear negotiation will once again commence this week as the US mulls removing some tariffs to salvage the deal. Meanwhile, heightened tensions between Ukraine and Russia have seeped into the west after US sent two warships to express its presence in the Black Sea in a bid to deter Russia. Ukraine's Foreign Ministry also stated that Russia has boycotted attempts to commence dialogue over the increased military presence on the Ukraine border as over 40k troops have been amassed by Moscow is both Crimea and Ukraine's eastern border. It's also worth keeping China tensions on the radar as US Secretary of State Blinken said the US is concerned about China's aggressive actions against Taiwan. On the demand side, COVID continues to be the overarching theme as India overtook Brazil as the worst-hit country by the pandemic, while over in Europe, Germany reportedly sees six to eight weeks of heightened infections and could see longer restrictions than initially expected. On the flip side, Britain has eased its respective COVID-related restrictions with most of the services sector seeing a controlled re-opening. WTI May resides around USD 59.85/bbl (vs low USD 58.73/bbl) while Brent Jun sees itself near USD 63.50/bbl (vs low USD 62.41/bbl). Elsewhere, spot gold and silver have been uneventful, contained within recent ranges and mirroring Dollar action as the metals await fresh catalysts. In terms of base metals, LME copper eases further from the USD 9,000/t mark as it mimics similar action seen in the Shanghai contract overnight as Chinese markets succumbed to softness. Chinese steel futures also saw losses on concerns over disruption as Premier Li pledged to tighten control of iron ore. That being said, participants expected the April-June period to see a notable increase in Chinese construction activity. Note, the China Iron & Steel Association will hold a meeting on April 13.

US Event Calendar

  • 2pm: March Monthly Budget Statement, est. -$658b, prior -$310.9b

Central Banks

  • 1pm: Fed’s Rosengren Discusses Economic Outlookd

DB's Henry Allen concludes the overnight wrap

Good morning and hope you all had a great weekend. At our end, its been a slightly more stressful than normal start as our remote access suffered from global issues this morning and none of us could log on. As a result, we haven’t included our usual tables so as to get this out as soon as we could, though we’re hoping they’ll be back tomorrow. I’m just hoping by the time you see this we haven’t become the Late Morning Reid...

IT issues aside, after another bumper week for risk assets that saw equity markets reach new highs, markets in Asia have lost ground this morning with the Nikkei (-0.52%), the Shanghai Comp (-0.81%) and the Hang Seng (-0.98%) all moving lower, as have S&P 500 futures (-0.27%). The moves follow an interview by Fed Chair Powell with CBS’ 60 Minutes that was released last night but conducted on Wednesday, in which he described the US economy as at an “inflection point”. Powell said that “We feel like we're at a place where the economy's about to start growing much more quickly and job creation coming in much more quickly”, in a tone that contrasted with his some of his more downbeat messaging where he’s emphasised how far the labour market still has to travel to get back to its pre-Covid state. He did still say that “there are something like 8.5, 9 million people, maybe even more than that depending on how you count it, who were working in February of last year before the pandemic and have lost their jobs”, but also said that “The good news is that we’re starting to make progress now.”

Another important story over the weekend came from Germany, where the Bavarian premier, Markus Soeder of the CSU, said publicly for the first time yesterday that he was willing to be the CDU/CSU chancellor candidate in September’s federal election, if the CDU were to support him. Normally the joint chancellor candidate would come from the larger CDU, whose leader Armin Laschet is also seeking the post. However, Soeder has strong approval ratings whereas the CDU/CSU bloc have seen a sharp polling decline over the last couple of months, with Bloomberg’s average last week putting them at 26.9%, which is down 6 percentage points from the last election back in 2017. In turn, this has raised the possibility that they might not be part of the federal government after September’s election, which would be the first time the party isn’t in government since Merkel became Chancellor back in 2005. Alternative coalition options have been in focus, though the Greens are the potential kingmakers in any scenario, since the party is now polling at 21.5% in the Bloomberg average (up from 8.9% in 2017). Speaking of Germany, our research colleagues in Frankfurt have published a note looking at what to do about sovereign risk on bank balance sheets. In their report, they say how the issue has still not been tackled, in contrast to other risk mitigation measures introduced by the Banking Union and that it remains the elephant in the room. You can see the full report here.

Turning to the week ahead now, the pandemic will remain in focus as the new case count is still moving higher at the global level. In the week ending last Friday April 9, the numbers recorded by John Hopkins University showed a 4.45m increase in cases globally, which compares with increases of 4.11m, 3.78m and 3.29m in the 3 weeks before that, so we’ve definitely seen an acceleration in the past month, although the rate of increase is still shy of the peaks in December and January. Some countries have been hit particularly badly by the latest wave, with India seeing another record 152,879 cases on Saturday. Japan is another that’s seen some sharp rises lately, and the governor of Osaka prefecture said over the weekend that he could request a state of emergency be declared if the latest measures weren’t enough to stem the virus.

Over in Europe, there’s been slightly more positive news in recent days, since the latest numbers from the biggest countries (Germany, France and Italy) indicate that cases have now begun to fall from their peak, albeit still at elevated levels. Furthermore, there are signs of the market narrative turning as the pace of vaccinations are continuing to pick up in the region, with the Euro strengthening +1.19% against the US dollar last week, in its best of 2021 so far, while 5y5y forward inflation swaps for the Euro Area closed at 1.57% on Friday, a level not seen since the very start of 2019. On top of that, the UK reported fewer than 2,000 cases yesterday for the first time since early September, which comes as today marks a notable easing of restrictions in England, with the reopening of non-essential retail and outdoor hospitality venues. Finally in other vaccine news, Pfizer and BioNTech said on Friday that they’d requested their Emergency Use Authorization for their vaccine in the US be extended to 12-15 year olds, following trial results that showed the vaccine was 100% effective among this group.

It’s a big week on the data side too, with a number of important releases out of the US set to offer more details on the strength of the recovery there. This comes against the backdrop of a very strong jobs report for March and an ISM services reading that was the highest since the series began back in 1997. This week’s highlight will be the CPI report on Tuesday, as market participants have focused on the potential for a sharp rise in the reading over the months ahead. Our US economists are expecting a +0.48% month-on-month increase in the headline CPI, along with some strong releases elsewhere as well, with a projected +8.9% increase in retail sales for March thanks to the latest round of stimulus checks and payback from bad weather in February. The other big data release this week will come from China, where they’re releasing their Q1 GDP number on Friday. Our economists are expecting a surge in growth to +21.3% year-on-year, up from +6.5% in Q4, as the comparison will now be against the quarter when the pandemic first impacted the Chinese economy.

On the central bank side, we’ll have to wait until next week before the latest round of policy decisions, with the ECB announcing a week on Thursday, before the Fed and the Bank of Japan follow the week after that. Nevertheless, this week is the last chance various Fed speakers will have to offer their thoughts before their blackout period begins on Saturday, and markets will be looking out for Fed Chair Powell on Wednesday, who’s giving an interview at the Economic Club of Washington, as well as from Vice Chair Clarida later that day, who’s giving a speech on the Fed’s new framework and outcome-based forward guidance. In terms of what to expect, our US economists are expecting them to reiterate their familiar inflation mantra, in that they’ll look through the upcoming sharp rise in the year-on-year growth rate of consumer price measures, along with the “transitory” spikes caused by temporary supply-demand imbalances as the economy reopens.

Elsewhere, the latest earnings season will kick into gear over the week ahead, with the highlights including a number of US financials. In their preview of the Q1 season (link here), our asset allocation team write that they see S&P 500 earnings coming in 7.5% above consensus, which although lower than the last 3 quarters, would still be well above the historical average (+4%). Looking at the biggest names releasing this week, they include JPMorgan Chase, Wells Fargo, Goldman Sachs and Tesco on Wednesday. Then on Thursday we’ll hear from UnitedHealth Group, Bank of America, PepsiCo, Citigroup, Charles Schwab, BlackRock and Delta Air Lines. And on Friday, releases will include Morgan Stanley and BNY Mellon.

Looking back at last week now, risk assets in Europe and the US finished at record highs as global bond yields took a breather from their steep climb in the first quarter. The MSCI World index rose every day, advancing +2.40% on its way to all-time highs, with its run of gains now extending to 8 successive sessions. The S&P 500 added +2.71% on the week, finishing at yet another record high following a +0.77% gain on Friday, and marking its largest weekly gain since the first week of February. The move was driven by a strong rebound in technology stocks as the NASDAQ rose +3.12% on the week, while the highly concentrated megacap NYFANG index rose +4.75% over the course of the week. The latter index has now risen for ten straight sessions through Friday’s close in a run that has seen it rise just over 10%. Market volatility has also calmed over recent weeks and this the VIX volatility index fell -0.64pts to 16.69, which is its lowest level since the pandemic started. European stocks similarly rose to their own record highs as the STOXX 600 gained +1.16% over the shortened week, with the FTSE 100 (+2.65%) outperforming other bourses against the backdrop of sterling’s biggest weekly decline so far this year (-0.90% vs USD).

Over in rates, US 10yr yields finished the week -6.3bps lower (+3.9bps Friday) at 1.659% - the second weekly drop in yields over the last three weeks. The global benchmark has traded between 1.60 and 1.75% over the last month, and last week’s move was driven by the drop in inflation expectations (-4.6bps), which was larger than the decline in real yields (-1.9bps). European rates were more mixed however, with 10yr bund yields gaining +2.5bps last week and UK gilts falling -2.1bps. There was also a notable widening of peripheral spreads in Southern Europe relative to bunds, with the spread of Italian BTPs (+7.1bps), Spanish bonds (+4.4bps), and Portuguese bonds (+4.4bps) all widening over the week.

Tyler Durden Mon, 04/12/2021 - 07:50

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

Trending